Activation peptide of carboxypeptidase B and anionic trypsinogen as early predictors of the severity of acute pancreatitis

British Journal of Surgery

Volumn 88, Issue 2, 2001, Pages 216-221

  Appelros, S ^a   Petersson, U ^b   Toh, S ^a   Johnson, C ^a   Borgstrom A ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE B; ENZYME ACTIVATOR; TRYPSINOGEN;

ACCURACY; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL;

EID: 0035136464     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2001.01672.x     Document Type: Article

References (25)

1. Early antibiotic treatment in acute necrotizing pancreatitis
2. Arandomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem
3. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis
4. Controlled clinical trial of perfloxacin versus imipenem in severe acute pancreatitis
5. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis
6. Early treatment with lexipafant, a platelet activating factor (PAF) antagonist, reduces morbidity and mortality from acute pancreatitis: A double blind, randomised, placebo controlled study
7. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis
8. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis
9. Pancreatic proteases and antiproteases in pancreatic disease; biochemical, pathophysiological and clinical aspects
10. The relationship between pancreatic enzyme release and activation and the acute-phase protein response in patients with acute pancreatitis
11. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis
12. Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis
13. Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis
14. Urine trypsinogen-2 as marker of acute pancreatitis
15. Serum trypsinogen-2 in the prediction of outcome in acute necrotizing pancreatitis
16. A clinically based classification system for acute pancreatitis
17. Immuno-reactive anionic and cationic trypsin in human serum
18. Different patterns in immunoreactive anionic and cationic trypsinogen in urine and serum in human acute pancreatitis
19. Studies on the turnover of procarboxypeptidase B, its active enzyme and the activation peptide in the pig
20. Receiver-operating characteristics (ROC) plots: A fundamental evaluation tool in clinical medicine
21. Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis
22. Evolution of pancreatitis
23. Urinary trypsinogen-2 test strip for acute pancreatitis
24. Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis
25. Mechanism of increased renal clearance of amylase/creatinine in acute pancreatitis